Abstract:Introduction: To determine the proportion of radiationinduced pneumonitis and pericarditis in patients who have received Hypo-fractionated Radiation along with simultaneous integrated boost technique after breast conservative surgery using a prospective observational study from a tertiary hospital. Materials & methods: The incidence of radiationinduced pneumonitis and pericarditis was evaluated in all adult patients with biopsy-proven early-stage unilateral breast cancer who underwent breast-conserving surgery followed by hypo-fractionated radiation with a simultaneous integrated boost technique. Baseline assessments including a six-minute walk test, highresolution computed tomography (HRCT), pulmonary function tests (PFTs), electrocardiography (ECG) and echocardiography (ECHO) were performed. At three months post-radiation treatment, patients underwent follow-up assessments with a six-minute walk test, ECG and ECHO. At six months post-radiation treatment, patients underwent further assessments with a six-minute walk test, ECG, ECHO, PFTs, and HRCT of the thorax. Data analysis was performed using SPSS version 19. Results: Our study investigated the incidence of acute radiation-induced pneumonitis and pericarditis in patients treated with hypofractionated VMAT-SIB technique in 20 eligible early breast cancer patients. The study found that the technique is feasible and achieves encouraging dosimetric parameters, including well achieved ipsilateral lung and heart doses. The reduced treatment time of 3-4 weeks compared to the previous 6-7 weeks with sequential boost was also found to be desirable in resource-constrained settings. The incidence of acute radiation pneumonitis and pericarditis was acceptable and comparable to existing data, with 90% of patients experiencing grade 1 radiation pneumonitis according to CTCAE v5.0. Post-treatment pulmonary function tests showed significant changes, particularly in patients who had received neoadjuvant chemotherapy and nodal irradiation. The six-minute walk test and Borg scale also showed a significant positive correlation with pulmonary function tests. There was no significant pericarditis during the follow-up. The study proposes that the hypofractionated radiotherapy using VMAT-SIB is a suitable alternative to conventional fractionation, with acceptable acute toxicities, but longer follow-up is required to assess the impact on late toxicities. Conclusion: Our research has shown that hypofractionated adjuvant radiotherapy with SIB is a safe and feasible treatment for patients with early breast cancer. This treatment method doesn't pose any significant short-term risks to the lungs or heart, and the SIB technique provides better coverage, conformity and sparing of organs at risk. Additionally, patients have reported positive cosmetic outcomes with this treatment. However, to make more accurate conclusions, we need to conduct further studies with larger sample sizes and longer follow-up periods to evaluate the potential longterm side effects of this treatment using VMAT in whole breast radiation.

Acute Toxicity Effect of Hypofractionated Whole-Breast Radiation Therapy with Simultaneous Boost of the Tumor Bed in Patients with Breast-Conserving Treatment

Hypofractionated versus Conventional Postmastectomy Irradiation for Breast Cancer: Comparison of Acute Skin Toxicity

Accelerated Hypofractionated Whole-Breast Irradiation with Concomitant Daily Boost Using Intensity-Modulated Radiation Therapy in Early Breast Cancer

HELICAL TOMOTHERAPY FOR WHOLE-BRAIN IRRADIATION WITH INTEGRATED BOOST TO MULTIPLE BRAIN METASTASES: DOSIMETRIC ANALYSISANDCLINICAL OUTCOMES

Are We Missing Acute Toxicities Associated with Hypofractionated Breast Irradiation? A Report from a Large Multi-Center Cohort Study

Results of a Clinical Phase II Trial of Whole Breast Irradiation with a Hypofractionated Simultaneous Integrated Boost to the Tumor Bed after Breast-Conserving Surgery for Early Breast Cancer

Clinical Results of Phase 2 Study of Whole-Breast Irradiation with Simultaneously Integrated Tumor Bed Boost (WBI-SIB): A Single-Center Experience

Postmastectomy Hypofractionation Radiotherapy in High-Risk Breast Cancer Patients: A Phase Ⅰ/Ⅱ Clinical Trial

Abstract GS5-12: Hypofractionated Radiotherapy in patients with Breast Cancer (HRBC): Acute toxicity data of a phase III randomized study

Assessment of Radiation Induced Pneumonitis and Pericarditis in Patients Undergoing Breast Conservative Treatment Using Hypofractionated Simultaneous Integrated Boost Technique

Post Mastectomy Linac IMRT Irradiation of Chest Wall and Regional Nodes: Dosimetry Data and Acute Toxicities

Hypofractionated whole breast irradiation after IORT treatment is safe in patients receiving adjuvant chemotherapy

Hypofractionated Whole-Breast Irradiation Focus on Coronary Arteries and Cardiac Toxicity-A Narrative Review

Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort

Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center

Comparison of two radiation boost schedules in postlumpectomy patients with breast cancer

Prospective Evaluation of Skin Toxicities in Patients Receiving Post-Mastectomy Irradiation of Chest Wall, Supra/infraclavicular and Internal Mammary Nodes Delivered by Conventional Versus Intensity-Modulated Radiotherapy Technique

Hypofractionated Stereotactic Radiation Therapy for Advanced Non-Small Cell Lung Cancer: Report on Clinical Outcome and Toxicity

Evidence from a breast cancer hypofractionated schedule: late skin toxicity assessed by ultrasound

Ultra-Hypofractionated Whole Breast Radiotherapy with Automated Hybrid-VMAT Technique: A Pilot Study on Safety, Skin Toxicity and Aesthetic Outcomes

The effect of radiotherapy time and dose on acute hematologic toxicity during concurrent postoperative chemoradiotherapy for early high-risk cervical cancer